Precision medicine has been widely acknowledged by scientists and physicians nowadays. The application of high-throughput omics technologies has provided a panorama of diseases at multiple levels. Thus, many diseases are reclassified based on their molecular spectrums for the purposes of personalized management. In recent years, plenty of research has been conducted to translate the omics/basic studies to clinical practice and precision treatment. In spite of the large number of new studies reported every year, very few clinical tools, products, or medications are finally developed for daily clinical practice due to different reasons. This topic is particularly important in genitourinary cancers as the most common malignancies worldwide.
The application of new omics-based approaches, such as genetic profiling for several genes (germline or somatic), biomarkers, etc., were still limited. In fact, the clinical impact of many scientific findings remains unclear. It may due to: (1) lack of causal inference in addition to association studies, whose results should be further investigated to confirm the causal relationship with diseases, i.e. biological functional studies, appropriate epidemiological and bio-statistical causal inference approaches, etc.; (2) lack of evidence bridging the scientific results to clinical practice, i.e. clinical trials, real-world evidence, outcomes studies, etc.; (3) unclear impact of the new approaches in terms of benefits/harms, socioeconomic impacts, cost-effectiveness, etc. The major goal of this Research Topic is to provide additional evidence for these problems in the field of urological oncology.
In this Research Topic, we would like to invite contributors from different fields to provide opinions and evidence of precision medicine and translational research for genitourinary cancers (prostate, bladder, kidney, etc.)
The studies may include:
1) Association studies and causal inference studies (via biological functional studies or appropriate epidemiological and bio-statistical causal inference approaches)
2) Translational studies from science to practice
3) Evaluation of the current precision medicine tools in terms of benefits/harms, socioeconomic impacts, cost-effectiveness etc,
4) Opinions of precision medicine in genitourinary cancers.
We would like to accept different types of articles in the scope including research articles (original research or clinical trial), review (systematic review or mini review), perspective/opinion, and methodology (methods, data report, or study protocol).
Precision medicine has been widely acknowledged by scientists and physicians nowadays. The application of high-throughput omics technologies has provided a panorama of diseases at multiple levels. Thus, many diseases are reclassified based on their molecular spectrums for the purposes of personalized management. In recent years, plenty of research has been conducted to translate the omics/basic studies to clinical practice and precision treatment. In spite of the large number of new studies reported every year, very few clinical tools, products, or medications are finally developed for daily clinical practice due to different reasons. This topic is particularly important in genitourinary cancers as the most common malignancies worldwide.
The application of new omics-based approaches, such as genetic profiling for several genes (germline or somatic), biomarkers, etc., were still limited. In fact, the clinical impact of many scientific findings remains unclear. It may due to: (1) lack of causal inference in addition to association studies, whose results should be further investigated to confirm the causal relationship with diseases, i.e. biological functional studies, appropriate epidemiological and bio-statistical causal inference approaches, etc.; (2) lack of evidence bridging the scientific results to clinical practice, i.e. clinical trials, real-world evidence, outcomes studies, etc.; (3) unclear impact of the new approaches in terms of benefits/harms, socioeconomic impacts, cost-effectiveness, etc. The major goal of this Research Topic is to provide additional evidence for these problems in the field of urological oncology.
In this Research Topic, we would like to invite contributors from different fields to provide opinions and evidence of precision medicine and translational research for genitourinary cancers (prostate, bladder, kidney, etc.)
The studies may include:
1) Association studies and causal inference studies (via biological functional studies or appropriate epidemiological and bio-statistical causal inference approaches)
2) Translational studies from science to practice
3) Evaluation of the current precision medicine tools in terms of benefits/harms, socioeconomic impacts, cost-effectiveness etc,
4) Opinions of precision medicine in genitourinary cancers.
We would like to accept different types of articles in the scope including research articles (original research or clinical trial), review (systematic review or mini review), perspective/opinion, and methodology (methods, data report, or study protocol).
